Logo image of FHTX

FOGHORN THERAPEUTICS INC (FHTX) Stock Fundamental Analysis

USA - NASDAQ:FHTX - US3441741077 - Common Stock

4.36 USD
+0.36 (+9%)
Last: 11/7/2025, 8:00:00 PM
4.27 USD
-0.09 (-2.06%)
After Hours: 11/7/2025, 8:00:00 PM
Fundamental Rating

2

Taking everything into account, FHTX scores 2 out of 10 in our fundamental rating. FHTX was compared to 531 industry peers in the Biotechnology industry. FHTX may be in some trouble as it scores bad on both profitability and health. FHTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FHTX had negative earnings in the past year.
FHTX had a negative operating cash flow in the past year.
FHTX had negative earnings in each of the past 5 years.
In the past 5 years FHTX reported 4 times negative operating cash flow.
FHTX Yearly Net Income VS EBIT VS OCF VS FCFFHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

FHTX's Return On Assets of -35.19% is fine compared to the rest of the industry. FHTX outperforms 62.15% of its industry peers.
Industry RankSector Rank
ROA -35.19%
ROE N/A
ROIC N/A
ROA(3y)-30.61%
ROA(5y)-27.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FHTX Yearly ROA, ROE, ROICFHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

1.3 Margins

FHTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FHTX Yearly Profit, Operating, Gross MarginsFHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

FHTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
FHTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FHTX has more shares outstanding
There is no outstanding debt for FHTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FHTX Yearly Shares OutstandingFHTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
FHTX Yearly Total Debt VS Total AssetsFHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

FHTX has an Altman-Z score of -4.36. This is a bad value and indicates that FHTX is not financially healthy and even has some risk of bankruptcy.
FHTX has a Altman-Z score (-4.36) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.36
ROIC/WACCN/A
WACC8.75%
FHTX Yearly LT Debt VS Equity VS FCFFHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

FHTX has a Current Ratio of 2.16. This indicates that FHTX is financially healthy and has no problem in meeting its short term obligations.
FHTX's Current ratio of 2.16 is on the low side compared to the rest of the industry. FHTX is outperformed by 73.07% of its industry peers.
FHTX has a Quick Ratio of 2.16. This indicates that FHTX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of FHTX (2.16) is worse than 71.37% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 2.16
FHTX Yearly Current Assets VS Current LiabilitesFHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.15% over the past year.
FHTX shows a decrease in Revenue. In the last year, the revenue decreased by -3.91%.
The Revenue has been growing by 157.75% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)41.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.35%
Revenue 1Y (TTM)-3.91%
Revenue growth 3Y157.75%
Revenue growth 5YN/A
Sales Q2Q%4.42%

3.2 Future

Based on estimates for the next years, FHTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.00% on average per year.
Based on estimates for the next years, FHTX will show a very strong growth in Revenue. The Revenue will grow by 27.28% on average per year.
EPS Next Y26.44%
EPS Next 2Y14.35%
EPS Next 3Y8.21%
EPS Next 5Y13%
Revenue Next Year2.76%
Revenue Next 2Y8.6%
Revenue Next 3Y14.83%
Revenue Next 5Y27.28%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
FHTX Yearly Revenue VS EstimatesFHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
FHTX Yearly EPS VS EstimatesFHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FHTX. In the last year negative earnings were reported.
Also next year FHTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FHTX Price Earnings VS Forward Price EarningsFHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FHTX Per share dataFHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.35%
EPS Next 3Y8.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FHTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FOGHORN THERAPEUTICS INC

NASDAQ:FHTX (11/7/2025, 8:00:00 PM)

After market: 4.27 -0.09 (-2.06%)

4.36

+0.36 (+9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners72.73%
Inst Owner Change-4.91%
Ins Owners7.96%
Ins Owner Change0%
Market Cap246.47M
Revenue(TTM)24.52M
Net Income(TTM)-72.12M
Analysts84.62
Price Target11.9 (172.94%)
Short Float %1.83%
Short Ratio5.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.9%
Min EPS beat(2)23.44%
Max EPS beat(2)26.37%
EPS beat(4)4
Avg EPS beat(4)18.49%
Min EPS beat(4)10.09%
Max EPS beat(4)26.37%
EPS beat(8)8
Avg EPS beat(8)21.63%
EPS beat(12)11
Avg EPS beat(12)18.92%
EPS beat(16)12
Avg EPS beat(16)9.32%
Revenue beat(2)2
Avg Revenue beat(2)21.5%
Min Revenue beat(2)14.02%
Max Revenue beat(2)28.98%
Revenue beat(4)3
Avg Revenue beat(4)-4.62%
Min Revenue beat(4)-61.83%
Max Revenue beat(4)28.98%
Revenue beat(8)6
Avg Revenue beat(8)1.01%
Revenue beat(12)8
Avg Revenue beat(12)18.87%
Revenue beat(16)9
Avg Revenue beat(16)26.35%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.07%
EPS NY rev (1m)0%
EPS NY rev (3m)11.57%
Revenue NQ rev (1m)5.83%
Revenue NQ rev (3m)-7.14%
Revenue NY rev (1m)-0.92%
Revenue NY rev (3m)6.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.05
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-1.57
FCFYN/A
OCF(TTM)-1.56
OCFYN/A
SpS0.43
BVpS-1.59
TBVpS-1.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.19%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.61%
ROA(5y)-27.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.07%
Cap/Sales 2.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 2.16
Altman-Z -4.36
F-Score3
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)33.62%
Cap/Depr(5y)290.03%
Cap/Sales(3y)4.61%
Cap/Sales(5y)806.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.35%
EPS Next Y26.44%
EPS Next 2Y14.35%
EPS Next 3Y8.21%
EPS Next 5Y13%
Revenue 1Y (TTM)-3.91%
Revenue growth 3Y157.75%
Revenue growth 5YN/A
Sales Q2Q%4.42%
Revenue Next Year2.76%
Revenue Next 2Y8.6%
Revenue Next 3Y14.83%
Revenue Next 5Y27.28%
EBIT growth 1Y14.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.02%
EBIT Next 3Y8.3%
EBIT Next 5YN/A
FCF growth 1Y26.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.07%
OCF growth 3YN/A
OCF growth 5YN/A

FOGHORN THERAPEUTICS INC / FHTX FAQ

Can you provide the ChartMill fundamental rating for FOGHORN THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to FHTX.


What is the valuation status for FHTX stock?

ChartMill assigns a valuation rating of 0 / 10 to FOGHORN THERAPEUTICS INC (FHTX). This can be considered as Overvalued.


What is the profitability of FHTX stock?

FOGHORN THERAPEUTICS INC (FHTX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for FOGHORN THERAPEUTICS INC?

The Earnings per Share (EPS) of FOGHORN THERAPEUTICS INC (FHTX) is expected to grow by 26.44% in the next year.